Immunological cross-reactivity among nematodes has hampered the development of specific serodiagnostic assays for onchocerciasis. In 
Introduction
Onchocerciasis, a disease caused by the filarial nematode Onchocerca volvulus, affects an estimated 20 million people in Africa and Latin America (1) . The parasite is transmitted by bites of Simulium black flies. The most important clinical manifestations of onchocerciasis are blindness and severe chronic dermatitis caused by immunopathological reactions to parasite larvae (microfilariae) in tissues (1) . At present, the parasitological diagnosis of human onchocerciasis depends pri-marily on the demonstration of microfilariae in skin snips. However, skin snip examination is not sensitive for detection of early infections or for diagnosis of individuals with low microfilaria densities in skin (2, 3) . Improved methods for diagnosis of such infections would aid in the assessment of control programs that attempt to interrupt transmission of onchocerciasis by vector control (4) or by mass chemotherapy with the microfilaricide ivermectin (5) .
Attempts to develop antibody serological tests for early diagnosis of onchocerciasis have been hampered by poor specificity caused by immunological crossreactivity between 0. volvulus and sympatric parasites. To be useful, an immunodiagnostic test for onchocerciasis should be at least as sensitive as skin snip examination, provide a species-specific diagnosis, and be practical for use in endemic areas. In addition to antigenic sharing, a second problem that has inhibited progress is that 0. volvulus parasite material is very difficult to obtain; the worms cannot be propagated in vitro or in laboratory animals and must be manually isolated from subcutaneous nodules that are surgically removed from human patients. To some extent, such problems can be side-stepped by application of molecular biological methods that allow efficient screening of DNA expression libraries to identify potentially useful recombinant antigens and production ofselected antigens in quantities without requiring additional parasite material. This article describes studies performed to clone and characterize recombinant 0. volvulus antigens that might be useful for immunodiagnosis of onchocerciasis.
Methods
Human sera. Nigerian sera were collected in Jago, a forest zone village near Ibadan, Nigeria. The diagnosis of onchocerciasis was based on clinical examination for subcutaneous nodules or onchocercal dermatitis and examination ofat least four skin snips per person as previously described (6) . Guatemalan onchocerciasis sera were collected from residents of coffee plantations in the Lake Atitlan endemic area (municipalities of Acatenango and Chicacao (Sigma Chemical Co., St. Louis, MO) (PBS/T), filters were incubated in diluted sera at 4°C overnight with gentle rocking. Human serum pools were diluted 1:500 in PBS/T and absorbed with E. coli antigens before use. Antibody reactivity with recombinant proteins was revealed by incubation offilters with alkaline phosphatase conjugated goat antihuman IgG antibodies (Promega Biotec, Madison, WI) for 3 h at 37°C and development with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT, Sigma Chemical Co.). Clones that were reactive with the 0. volvulus serum pool but not with the omnibus antinematode serum pool were selected and purified by repeated cycles of immune selection.
Plaque-dot immunoblots. The reactivity ofserum pools and ofindividual human sera to fusion proteins expressed by purified recombinant phage was studied by plaque-dot immunoblot analysis. Recombinant phage (I03 pfu in 1 Al) was spotted in a prearranged grid onto an E. coli Y1090 lawn on Luria-Bertani agar with ampicillin. Plates were incubated at 420C until just before complete lysis of phage spots occurred. Nitrocellulose filters were placed on plates overnight at 321C.
After blocking, filters were cut into 0.8-mm strips and probed with sera that had been preadsorbed by incubation with E. coli antigens bound to nitrocellulose. The dot blots were then processed as described above to detect antibodies bound to recombinant protein except that individual human sera were tested at a dilution of 1:100.
Polymerase chain reaction (PCR). PCR was employed to amplify the cDNA inserts ofselected recombinant lambda gtl 1 clones with the Gene Amp DNA amplification kit (Perkin Elmer-Cetus, Norwalk, CT) according to the manufacturer's instructions. The amplified products of PCR were identified and insert sizes were determined by agarose gel electrophoresis.
Immunoblot analysis ofrecombinantfusion proteins. E. coli Y 1090 was infected at high density with recombinant phage on a thin layer of agarose over LB agar to achieve confluent lysis, and synthesis offusion proteins encoded by cDNA inserts was induced with IPTG-impregnated filters as described above. Top agarose containing bacterial lysate and fusion protein was then gently scrapped offand dissolved in SDS-PAGE sample buffer. SDS-PAGE was performed as described by Laemmli (9) at 135 V in 8% reducing gels. After SDS-PAGE, proteins were electrophoretically transferred to nitrocellulose membrane (BA 83; Schleicher & Schuell, Inc., Keene, NH) as described by Towbin et al. (10) . After transfer, nitrocellulose membranes were blocked in 5% nonfat dry milk in PBS/T for 3 h at 370C. Membranes were then incubated in monoclonal antibody to fl-galactosidase (Promega Biotec) or in human sera diluted in PBS/T overnight at 4°C. Membranes were washed in PBS/T and incubated with alkaline phosphatase conjugated goat anti-mouse IgG or anti-human IgG (Promega Biotec) for 3 h at 37°C. After washing, membranes were developed with BCIP/NBT. DNA sequencing. Lambda gtlI DNA purified from selected clones was digested with EcoRl and ligated into the EcoRl site ofpBluescript II SK-(Strategene Cloning Systems, La Jolla, CA) by standard methods (11) . Competent XLl-Blue cells were transformed with the ligation mix and plated onto LB-ampicillin plates with 40 #1 of 2% X-gal and 100 Ml of 0.1 M IPTG. The presence of DNA inserts in white colonies was determined by agarose electrophoresis of DNA isolated by the rapid boiling method (12). Next, plasmid DNA was prepared from selected colonies by standard methods for sequencing. The dideoxynucleotide chain termination method (13) was used for double stranded DNA sequencing using the TaqTrack Sequencing System (Promega Biotec) with T3 and T7 pBluescript primers and with synthetic oligonucleotide primers.
0. volvulus antigen. 0. volvulus adult worm crude worm extract and rabbit antibodies to this antigen were produced as previously described (6). Table I along with their DNA insert sizes. All seven clones were recognized by a serum pool comprising 12 sera from infected children (8-15 yr of age) from Jago, Nigeria, but only five were recognized by a serum pool comprising 12 sera from infected adults from the same village. Interestingly, rabbit antibodies to 0. volvulus reacted with only three of these clones. Immunoreactivity of individual human sera with these clones is summarized in Table II . The most immunoreactive clones were OC 3.6 and OC 9.3, which were recognized by 98% and 83% of onchocerciasis patient sera, respectively. Some of the endemic control sera also contained antibodies to antigens produced by these clones. These antibodies may indicate the presence ofearly infections in these individuals. Alternatively, antibody responses to the recombinant Molecular characterization of clones OC 3.6 and OC 9.3.
Western blot analysis showed that OC 3.6 and OC 9.3 produced fusion proteins with apparent molecular masses of 152 and 138 kD as shown in Fig. 1 . Species specificity of these recombinant antigens was demonstrated by Western blot analysis ofserum pools from patients infected with a variety ofother parasites (Fig. 2) . The DNA sequence of OC 9.3 is shown in Fig. 3 .2 A schematic diagram of the sequence is shown in Fig. 4 . The insert contains 565 bp with an open reading frame (ORF) of 382 bp, and it appears to include the entire coding region for the protein. Although there is no untranslated DNA at the 5' end ofthe sequence, we believe that the coding region begins with a methionine codon seven bp from the 5' end with a purine in the -3 position (16) . This sequence codes for a protein of 125 amino acids with a predicted molecular mass of 14.4 kD and a calculated pI of 5.09. The 3' untranslated region of the insert contains 183 bp and ends with a 13-bp poly-A tail which begins 12 bp downstream from the sequence ATTAAA, a previously described variant of the eukaryotic consensus polyadenylation signal (17) . Hydropathy analysis by the method of Hopp and Woods (18) predicts the protein to be predominantly hydrophilic (Fig. 5) . None of the hydrophobic stretches is long enough to comprise a membrane-spanning a helix, and the sequence does not contain N-glycosylation sites. These features suggest a cytoplasmic location for the protein. Computer searches failed to reveal significant homology between the DNA or predicted amino acid sequence of OC 9.3 with previously reported sequences in the Genbank and NBRF data bases.
The 996-bp DNA sequence of OC 3.6 is shown in Fig. 6.2 The sequence contains one 627-bp ORF, which begins at the 5' end in phase with the reading frame ofthe f3-galactosidase-gene of X gtl 1, and 369 bp of untranslated DNA at the 3' end. The protein encoded by the ORF contains 209 aminoacids and has a predicted molecular mass of 23.1 kD. OC 3.6 is closely related to an 0. volvulus clone, OV 33-3, previously described by Lucius et al. (19) . The sequence of OC 3.6 between bases 11 and 896 is identical to sequence in OV 33-3 (Fig. 7) . OC 3.6 lacks 102 bp of sequence that are present at the 5' end of the ORF ofOV 33-3. However, OC 3.6 contains 10 bp at the 5' end of its ORF and 100 bp in its 3' untranslated region that are not present in OV 33-3. The latter segment contains a polyadenylation signal and a 23 bp poly-A tail that are not present in the published sequence ofOV 33-3. A hydropathy plot ofthe composite sequence ofOV 33-3 and OC 3.6 is shown in Fig. 8 (19) . OC 3.6 produced a stable fusion protein that was recognized by antibodies in 54 of 55 sera from onchocerciasis patients tested. We have also found that this protein was recognized by sera from chimpanzees with prepatent and patent 0. volvulus infections (authors' unpublished observations). This sensitivity was achieved in spite of the fact that the OC 3.6 fusion protein lacks the terminal 34 amino acids of the protein encoded by OV 33-3. This finding and the results ofthe hydropathy analysis suggest that the amino terminal end of OV 33-3 is not important in determining its antigenic reactivity. However, additional studies are needed to determine the immunodominant domains of this protein.
In addition to the clones described in this paper, a number of other recombinant 0. volvulus antigens have been produced in other laboratories and proposed as immunodiagnostic antigens (19, 25, 26) . Cooperative studies sponsored by the Filariasis Steering Committee of the TDR Program of the World Health Organization are in progress to determine the relative diagnostic potential of these candidate antigens (C. P. Ramachandran, personal communication). This cooperative approach should accelerate development of a sensitive, specific, and practical antibody diagnostic test that will be useful for diagnosis of onchocerciasis in endemic countries.
